Drugs / RR-HNK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06575075 | Jan 2026 → Nov 2028 expected | obsessive-compulsive disorder | Carolyn Rodriguez | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RR-HNK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06575075 ↗ |
| Known as | Hydroxynorketamine | “Drug: RR-HNK/Hydroxynorketamine” NCT06575075 ↗ |
| Action | Inhibit | “a glutamate AMPA receptor antagonist” NCT06575075 ↗ |
| Route | Intravenous | “intravenous RR-HNK administration” NCT06575075 ↗ |